Evidence map›Paper›PMID 42088572›Full record

ArticleFrontiers in pharmacology2026

OGFOD1: a critical mediator of chemoresistance in acute myeloid leukemia.

Tingting Qiu, Peiyi Li, Liquan Tan, Shuang Wu, Qunli Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingting Qiu *Department of Hematopathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Peiyi Li *Respiratory Intensive Care Unit, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Liquan TanDepartment of Nursing, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Shuang WuRespiratory Intensive Care Unit, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Qunli LuoDepartment of Hematopathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2-oxoglutarate-and iron-dependent oxygenase domain-containing protein 1(OGFOD1) is a prolyl hydroxylase that plays a pivotal role in regulating protein synthesis accuracy and efficiency. OGFOD1 is implicated in the pathogenesis of various cancers, including lung cancer, breast cancer and colonic cancer. A recent study highlights that under chemotherapy pressure, the upregulation of OGFOD1 promotes global protein synthesis via its catalytic activity, which is a key mechanism for AML chemoresistance. Deleting of OGFOD1 specifically compromises AML translation adaptability, thereby eradicating post-chemotherapy resistant cells and extending survival

Indexed as

AMLBCAAOGFOD1protein synthesistranslation

Identifiers

PMID42088572
PMCPMC13136079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.